GLP-1s for Small Amounts of Weight Loss? What the Research Says

GLP-1 medications (you know them as Ozempic, Wegovy, Zepbound, and more) have quickly become tools for helping people with obesity and diabetes lose large amounts of weight when diet and exercise haven’t worked. But emerging research suggests these medicines also offer healthspan–extending benefits for people without obesity or diabetes.

That includes the 1 in 3 Americans who are considered overweight, with a body mass index (BMI) between 25 and 29—below the obesity threshold of 30. ¹ For people in this category, weight loss on GLP-1s is more modest, typically about 20 or 30 pounds. But the other benefits of Ozempic remain—it can restore the energy and cognitive bandwidth needed to maintain key longevity and lifestyle changes that lower risk for diabetes and heart disease and help people live better for longer.

For these reasons, a growing number of clinicians view GLP-1 medications as an essential ingredient in a well-rounded metabolic health optimization program, regardless of whether or not the patients in the program technically meet criteria for diabetes or obesity— the conditions for which the FDA originally approved them.

Losing 20 to 30 pounds on GLP-1 medications doesn’t replace exercise, nutrition, sleep, and other healthy lifestyle changes. Instead, taking a weight loss medication augments their effects and, in many cases, it makes those changes possible.

The Problems with Current GLP-1 Guidelines

Traditional medicine waits to prescribe GLP-1 medications until a patient’s BMI hits 30 (obesity) or 27 with at least one weight-related health condition, such as high blood pressure or high cholesterol. Clinicians can prescribe GLP-1s off-label for people with BMIs below 27, but insurance rarely picks up the cost.

Unfortunately, BMI—which measures only weight and height—is a poor gauge of body composition and overall health. It’s especially problematic for people in between the clinical diagnoses of “overweight” and “obesity.” Here’s why using GLP-1s to lose 10 to 30 pounds has benefits beyond a smaller waistline.

How Muscle Mass and Bone Density Skew BMI

BMI doesn’t reflect the difference between the weight of muscle and fat. Based on BMI alone, some very muscular people would qualify for GLP-1 treatment under current FDA guidelines, even though they don’t need it. Conversely, patients with BMIs of 25 or 26 who have low muscle mass (“skinny fat”) and might benefit metabolically from the medication don’t have access.

People with BMIs under 30 can be metabolically unhealthy.

Where people carry fat on their body—a metric BMI doesn’t measure—can mean the difference between healthy and unhealthy. ² Visceral fat, found around vital organs like the liver and pancreas, raises inflammation and accelerates biological aging more than subcutaneous fat, which resides just under the skin. People with more visceral fat (“apple shaped”) tend to have higher cholesterol, blood sugar, and blood pressure at a given bodyweight than those whose fat is more evenly distributed around the body (“hourglass” or “pear shaped”).

BMI doesn’t reflect patterns.

Two people can have the same BMI but drastically different future health risks. Compare two people at the same BMI, one with relatively higher muscle mass than the other. The first person will have an easier time keeping a stable weight, and the second is more likely to consistently gain, inching their way toward diabetes and cardiovascular disease. (Most women tend to gain 1.5 pounds per year and men tend to gain 1–2 pounds per year in midlife. ^{3 4}) Current FDA guidelines recommend waiting until this latter person becomes sick or obese (or both) to treat them with a GLP-1 medication. But by stopping and reversing this creeping fat gain, early intervention with a GLP-1 can prevent the resulting cascade of health problems.

BMI also doesn’t account for age, gender, or ethnic differences in disease risk.

A New Obesity Definition

Because BMI is such a flawed metric, the Lancet Commission—made up of 58 experts from multiple medical specialties and countries—in 2025 recommended redefining “overweight” as “preclinical obesity.” ⁵

And earlier this year, the European Association for the Study of Obesity (EASO) released a new obesity definition that includes many people who previously would have been considered overweight. ⁶

According to this new framework, people with a BMI of 25 or higher would be classified as having obesity if they also:

• Have a waist-to-height ratio of 0.5 or greater
• Have been diagnosed with medical, functional, or psychological issues related to excess body fat, such as elevated blood glucose, chronic low-grade inflammation, poor sleep, or binge eating.

Roughly one in five adults previously defined as overweight would be considered obese based on the new EASO definition—and would therefore be eligible for insurance reimbursement for GLP-1 treatment, according to a study published in the Annals of Internal Medicine. ⁷

Why Even Small Weight Loss Matters

People who are overweight (BMI in the 25 to 30 range) drop less weight on GLP-1s than those with clinical obesity, losing just 5 to 10 percent of their body weight on average versus 15 to 20 percent for the obese cohort.

These smaller losses may not seem as dramatic. However, they make major differences for longevity.

Hundreds of studies have linked small changes in weight to big benefits:

• Lower blood pressure: Reducing BMI by just 2.27 points—e.g., going from a BMI of 26 to a BMI of 23.7, or losing about 20 pounds—can lower systolic and diastolic blood pressure by 5.79 mmHg and 3.36 mmHg, respectively. ⁸
• Lessen knee pain: A 5 percent weight loss is enough to resolve knee pain in some people. ⁹
• Reduce cancer risk: Losing just 11 pounds is enough to significantly lower the risk of many types of cancer, including breast, ovarian, and colon, according to an analysis of 66 studies. ¹⁰
• Lower diabetes risk: In people with elevated blood sugar, for every 2.2 pounds of weight loss, the risk of developing diabetes drops 16 percent. ¹¹ In one study, losing just 5 percent of total body weight was enough to improve the function of insulin-secreting beta cells as well as insulin sensitivity.¹²
• Improve blood lipids: Improvements in triglycerides—fats in the blood—start with as little as 2 percent weight loss. ¹³ When people lose 5 percent of their body weight, total and LDL cholesterol levels also improve.¹⁴
• Promote sounder sleep: Losing 5 percent or more of one’s body weight is enough to reduce the number of respiratory events people with sleep apnea experience, and also improves insomnia and daytime sleepiness. ¹⁵

GLP-1s, technically glucagon-like peptide-1 receptor agonists, facilitate weight loss by slowing the movement of food through the gastrointestinal tract, increasing fullness, and suppressing appetite. Along the way, they help reduce inflammation and directly support heart, liver, and brain health, lessening the severity of sleep apnea, reducing the risk of heart attacks and premature mortality, easing joint pain, and boosting energy. ^{16 17 18}

Newly emerging indications for GLP-1 medications—including heart disease, metabolic liver disease, peripheral artery disease, Alzheimer’s/dementia risk, and even alcohol and substance use disorders, as highlighted in a 2025 study in JAMA¹⁹—suggest these drugs may soon play a much broader role in medicine than just treating diabetes or obesity. Taken together, the evidence points to a future where eligibility for GLP-1 treatment could expand significantly as guidelines catch up with the science.

Why GLP-1 Drugs Aren’t “Cheating”

Unfortunately, while growing numbers of clinicians understand the many benefits of GLP-1 medicines for early intervention and metabolic health optimization, not everyone is on board. Many traditional healthcare professionals either refuse to entertain any conversation about prescribing GLP-1 medicines or derisively tell patients they just need to try harder.

But GLP-1s are not a crutch or a form of cheating. It’s the opposite: Most people won’t lose 5 percent or more of their body weight without medical treatment.

Research shows that only about 1 in 10 people with a BMI of 25 or higher will lose 5 percent of their body weight and keep it off with lifestyle changes alone. ²⁰

For the remaining 9 in 10, a GLP-1 prescription can serve as a jumpstart, helping them lose enough weight to make important lifestyle changes possible. Others consider it simply leveling the playing field for individuals who’ve inherited genes associated with obesity.

Reduced cravings, food noise

“Food noise” is a relatively new term used to describe the incessant mental chatter around food that leads to overeating.

GLP-1s help quiet food noise by influencing the release of dopamine in the reward center of the brain. As their food noise ebbs, patients say they finally have the cognitive bandwidth to stick to healthier eating—reaching for more veggies, legumes, and lean proteins and fewer sweets and chips.

Take Amy Saunders, 45, of Stafford, Virginia, who found herself putting on weight while trying to quit smoking. Hitting the gym three to five days a week didn’t balance out the extra sweets she was eating, and soon Amy had put on 11 pounds and learned her blood sugar had risen. Her BMI was 24.5, just shy of the overweight threshold (and far from the FDA’s threshold of 30), but her physician OK’d a low dose of a GLP-1.

“I never understood what food noise was until it wasn’t there anymore,” Amy says. “The sugar cravings practically turned off. Surprisingly,” she adds, “the GLP-1 has also suppressed my nicotine cravings.”

Improved self-confidence

Losing even a little weight on GLP-1s, often just 10 to 30 pounds, often translates to vast improvements in self-esteem, which fuels healthy habits in a positive feedback loop.

Kimberly A., 53, of the greater Philadelphia area, had a BMI of 29 when she started taking a GLP-1. It not only silenced her food noise, helping her lose 10 pounds, but it also transformed her self-talk: “I noticed an absence of self-criticism about my body, weight and food habits,” she says.

Like Kimberly, Brie M., 46, of Indianapolis, had an elevated BMI of 28.9 but did not technically meet criteria by itself for obesity. She was having trouble shedding the 35 pounds she’d gained during perimenopause until GLP-1s helped her hit her goal weight within 100 days. Although she could up her dose of GLP-1s and lose more weight, Brie is happy where she is. “I’m just so grateful to be able to look at myself in the mirror and walk into a room without feeling self-conscious.”

The Downsides of GLP-1s for Moderate Weight Loss

These are the main downsides to GLP-1 medications:

• Side effects: The most common are gastrointestinal symptoms—nausea, diarrhea, and constipation. However, people who don’t have a lot of weight to lose can take a low dose of a GLP-1 medication, often preventing GI upset. Another possible side effect is muscle loss, but that’s an outcome of any means of weight loss and can be largely countered with strength training. Newer research also shows that for people with less weight to lose, the GLP-1s semaglutide and liraglutide help preserve muscle during weight loss. ²¹
• Cost: Out-of-pocket costs will depend on insurance coverage, manufacturer discounts, and the pharmacy used, but people who fall outside the clinical eligibility guidelines often don’t qualify for insurance coverage. The retail price of GLP-1 drugs currently run about $499 per month. Hone Health members can get the GLP-1 liraglutide for $160 per month, or tirzepatide for $349 for the first month and $499 a month thereafter.
• Dependence: Most patients need to stay on GLP-1s to keep the weight off, and those monthly costs add up over time.

About the author

Alisa Bowman is a professional science writer and certified nutrition coach. Her work has appeared in Discover Magazine, Self, and a variety of other outlets.

About the reviewer